Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Ryan Michael Thomas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9251-5543; OpenAlex author ID A5075684432; NIH RePORTER profile ID 8496918. Sources: ClinicalTrials.gov.

Their work

Papers
27 (first author 2, last author 3)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
1
Collaborators
63
Papers, trials and grants by year

2012: 5 papers · 2013: none · 2014: 3 papers · 2015: 5 papers, 1 trial · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 2 papers, 1 grant · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 27

  1. Dynasore as a dual modulator of lipid rafts and cell death in pancreatic cancer. Last author DOI 10.1016/j.neo.2025.101254↗
  2. Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial. Co-author DOI 10.1093/oncolo/oyag250↗
  3. Multifaceted effects of the microbiome in pancreatic cancer: from association to modulation. Co-author DOI 10.1038/s41575-025-01119-y↗
  4. A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. Co-author DOI 10.2217/fon-2023-0256↗
  5. The Prospect of Harnessing the Microbiome to Improve Immunotherapeutic Response in Pancreatic Cancer. Last author DOI 10.3390/cancers15245708↗
  6. Implications of the microbiome in the development and treatment of pancreatic cancer: Thinking outside of the box by looking inside the gut. Last author DOI 10.1016/j.neo.2020.12.008↗
  7. Protein Signatures and Tissue Diagnosis of Pancreatic Cancer. Co-author DOI 10.1016/j.jamcollsurg.2019.10.002↗
  8. Impact of Palliative Chemotherapy and Travel Distance on Hospice Referral in Patients With Stage IV Pancreatic Cancer: A Retrospective Analysis Within a Vetera… First author DOI 10.1177/1049909117746390↗
  9. Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine. Co-author DOI 10.3390/ijms19123836↗
  10. A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.09.038↗
  11. Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Co-author DOI 10.1158/0008-5472.can-16-1765↗
  12. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. Co-author DOI 10.1016/j.ajpath.2016.02.009↗
  13. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-15-1256↗
  14. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  15. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in hum… Co-author DOI 10.1007/s00262-015-1760-y↗
  16. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Co-author DOI 10.1016/j.ajpath.2015.01.016↗
  17. Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype. Co-author DOI 10.1038/labinvest.2014.143↗
  18. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. Co-author DOI 10.1186/s12885-015-1820-x↗
  19. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adeno… Co-author DOI 10.1245/s10434-014-4241-1↗
  20. Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer. Co-author DOI 10.1088/1478-3975/11/6/065002↗
  21. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Co-author DOI 10.1158/1078-0432.ccr-14-0970↗
  22. Transport properties of pancreatic cancer describe gemcitabine delivery and response. Co-author DOI 10.1172/jci73455↗
  23. Multi-color palette of fluorescent proteins for imaging the tumor microenvironment of orthotopic tumorgraft mouse models of clinical pancreatic cancer specimen… Co-author DOI 10.1002/jcb.24099↗
  24. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. Co-author DOI 10.1007/s11605-012-1912-8↗
  25. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration. First author DOI 10.1016/j.jamcollsurg.2012.03.024↗
  26. Imageable fluorescent metastasis resulting in transgenic GFP mice orthotopically implanted with human-patient primary pancreatic cancer specimens. Co-author PMID 22493347↗
  27. Non-invasive fluorescent-protein imaging of orthotopic pancreatic-cancer-patient tumorgraft progression in nude mice. Co-author PMID 22843874↗

Trials 1

  1. Circulating Tumor Cells in Operative Blood Principal investigator NCT02150746↗

Grants 1

  1. Microbiota-mediated enhancement of the anti-tumor effect of natural killer cells R21CA263462↗

Closest collaborators

The 25 strongest of 63 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christian Jobin · 1 shared paper, 1 shared grant, 2021–2023 · strength 1.00
  2. Steven J. Hughes · 11 shared papers, 2015–2026 · strength 0.93
  3. Thomas J. George · 8 shared papers, 2015–2026 · strength 0.70
  4. Sherise Chantell Rogers · 3 shared papers, 2023–2026 · strength 0.69
  5. Daniel Delitto · 9 shared papers, 2015–2020 · strength 0.54
  6. Jose Gilberto Trevino · 9 shared papers, 2015–2020 · strength 0.54
  7. Jakob S. Hamilton · 1 shared paper, 2026 · strength 0.50
  8. Matthew H. G. Katz · 11 shared papers, 2012–2016 · strength 0.39
  9. Jason B. Fleming · 11 shared papers, 2012–2016 · strength 0.39
  10. Omar Roger Kayaleh · 2 shared papers, 2023–2026 · strength 0.39
  11. Ibrahim Nassour · 2 shared papers, 2023–2026 · strength 0.39
  12. Kathryn E. Hitchcock · 2 shared papers, 2023–2026 · strength 0.39
  13. Jesus C. Fabregas · 2 shared papers, 2023–2026 · strength 0.39
  14. Shannon Margaret Wallet · 7 shared papers, 2015–2018 · strength 0.36
  15. K.E. Behrns · 7 shared papers, 2015–2017 · strength 0.36
  16. Mark Joseph Truty · 10 shared papers, 2012–2016 · strength 0.35
  17. Chen Liu · 6 shared papers, 2015–2017 · strength 0.29
  18. Song Han · 4 shared papers, 2015–2020 · strength 0.25
  19. Ya’an Kang · 6 shared papers, 2014–2016 · strength 0.24
  20. Deyali Chatterjee · 6 shared papers, 2014–2016 · strength 0.24
  21. Z. Hugh Fan · 1 shared paper, 2026 · strength 0.24
  22. Michael H. Gerber · 3 shared papers, 2017–2020 · strength 0.24
  23. Qin Yu · 1 shared paper, 2021 · strength 0.22
  24. Huamin Wang · 6 shared papers, 2012–2016 · strength 0.21
  25. Kien Pham · 4 shared papers, 2015–2017 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.